P2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR Signaling Pathways to Mediate Tumor Cell Death by Bian, Shu et al.
 
P2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR Signaling
Pathways to Mediate Tumor Cell Death
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Bian, Shu, Xiaofeng Sun, Aiping Bai, Chunqing Zhang, Linglin
Li, Keiichi Enjyoji, Wolfgang G. Junger, Simon C. Robson, and
Yan Wu. 2013. P2X7 integrates PI3K/AKT and AMPK-PRAS40-
mTOR signaling pathways to mediate tumor cell death. PLoS
ONE 8(4): e60184.
Published Version doi:10.1371/journal.pone.0060184
Accessed February 19, 2015 12:06:28 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11181002
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAP2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR














1Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, Jinan, People’s Republic of China, 2Department of Medicine, Transplant Institute,
Harvard Medical School, Boston, Massachusetts, United States of America, 3Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School,
Boston, Massachusetts, United States of America
Abstract
Background: Extracellular adenosine triphosphate (ATP) functions as a novel danger signal that boosts antitumor immunity
and can also directly kill tumor cells. We have previously reported that chronic exposure of tumor cells to ATP provokes
P2X7-mediated tumor cell death, by as yet incompletely defined molecular mechanisms.
Methodology/Principal Findings: Here, we show that acute exposure of tumor cells to ATP results in rapid cytotoxic effects
impacting several aspects of cell growth/survival, leading to inhibition of tumor growth in vitro and in vivo. Using agonist
and antagonist studies together with generation of P2X7 deficient tumor cell lines by lentiviral shRNA delivery system, we
confirm P2X7 to be the central control node transmitting extracellular ATP signals. We identify that downstream intracellular
signaling regulatory networks implicate two signaling pathways: the known P2X7-PI3K/AKT axis and remarkably a novel
P2X7-AMPK-PRAS40-mTOR axis. When exposed to high levels of extracellular ATP, these two signaling axes perturb the
balance between growth and autophagy, thereby promoting tumor cell death.
Conclusions: Our study defines novel molecular mechanisms underpinning the antitumor actions of P2X7 and provides a
further rationale for purine-based drugs in targeted cancer therapy.
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Introduction
Extracellular adenosine triphosphate (ATP) functions as a
danger signal, which is operational through type 2 purinergic
(P2) receptors. ATP initiates intracellular signaling cascades that
participate in many pathophysiological processes e.g. proliferation,
differentiation, apoptosis, inflammation, and metabolism [1–3].
There are two P2 receptor families that associate with ATP and
other nucleoside triphosphates and diphosphates: seven P2X
receptors (P2X127) that are ATP-gated ion channels and eight G
protein-coupled P2Y receptors (P2Y1, 2, 4, 6, 11–14). Different P2
receptors have differential agonist affinity/specificity whereby
modulating different cellular functions [4,5].
High levels of pericellular ATP are thought to exert antitumor
activity through various molecular mechanisms [2,6–8]. First, it
has been shown that ATP promotes antitumor immune responses
by: 1) enhancing dendritic cell-primed tumor specific CD8 T cell
cytotoxicity [9,10]; 2) acting as a ‘‘find-me’’ signal to phagocytes
[11]; 3) induction of IL-1b release by monocytes [12,13]; 4)
skewing of T helper (Th) cells towards type 1 (Th1) and type 17
(Th17) cells which are thought to promote antitumor immunity
[14–16]; and 5) limiting immunosuppressive activity by induction
of regulatory T cell (Treg) apoptosis [17,18]. Many of these effects
appear mediated via activation of P2X7 receptor but the direct
signaling pathways implicated are uncertain.
Additionally, high ATP levels have also been reported to exhibit
direct cytotoxicity on many types of tumor cells such as prostate
cancer, melanoma, glioma, and colon cancer cells [1,19]. Among
the fifteen P2 receptors, five subtypes specifically P2X5, P2X7,
P2Y1, P2Y2, and P2Y11 (human exclusive), have been associated
with the direct tumor-killing functions of ATP, but the precise
molecular mechanisms remain somewhat unclear [1].
More recently, our laboratory has shown that high levels of
extracellular ATP (eATP) effectively inhibit proliferation and
induce apoptosis/necrosis of tumor cells suggesting anti tumor
potential of purine-based drugs [15,20]. In these studies, tumor
cell death occurred as a result of the combined actions of ATP and
its purine derivatives e.g. adenosine diphosphate (ADP) and
adenosine. However, it is quite challenging to maintain eATP at
high levels in the tumor microenvironment for long periods
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chiefly CD39/ENTPD1 (nucleoside triphosphate diphosphohy-
drolase-1) by tumor-associated vascular, immune and stromal
cells, and/or tumor cells per se [2,21].
Although we have linked eATP-elicited tumor cell death to
P2X7 purinergic receptor [20], the intracellular signaling cascades
of eATP-P2X7 are not fully described. Signal transduction
networks are very complex and blockade of one component often
disrupts key negative feedback mechanisms resulting in aberrant
activation of compensatory pathways. As such, further defining the
components of cytotoxic ATP-initiated purinergic signaling
pathways is critical for the development of effective cancer
therapies. For example, the mammalian target of rapamycin
(mTOR) has been proven to be a promising cancer target and
several rapamycin-related compounds (rapalogs) are now in
various stages of clinical development as anticancer agents
[22,23]. However, rapalog exposure unfortunately disrupts crucial
negative feedback modulations causing subsequent activation of
phosphatidylinositol-3-OH kinase (PI3K)/protein kinase B (AKT)
and/or PI3K-mitogen-activated protein kinase (MAPK) pathways
and ultimately leading to chemoresistance [23,24]. Therefore, a
better understanding of the complexity of purinergic signaling
(inclusive of negative feed-back loops) will be required to
understand more clearly the biological consequences of inhibiting
specific components of these cellular regulatory networks, as in
cancer therapy.
We show here that brief exposure of tumor cells to ATP is able
to efficiently induce cell death (including reduction of cell growth
and induction of autophagy), mediated largely via P2X7. We
further delineate the downstream components of ATP-P2X7
signaling, namely the known links to the PI3K/AKT axis [25] and
a novel axis of AMP kinase (AMPK)-proline-rich AKT substrate of
40 KDa (PRAS40)-mTOR. These two seemingly independent
signaling axes appear to act synergistically in response to
tumoricidal ATP-P2X7 signals to thereby elicit maximal tumor
cell death by disrupting the balance between cell growth and
autophagy, without disturbing the negative feedback regulations as
those seen with rapalogs. Our data provide further evidence as
well as molecular basis for the utility of purine-based drugs as
adjunctive agents in cancer therapy.
Materials and Methods
Ethics Statement
All mice were kept in a pathogen-free, temperature-controlled
room with alternating 12hr dark/light cycles at the Beth Israel
Deaconess Medical Center (BIDMC) and were negative for tests of
Virology, Bacteriology, Infectious Disease PCR, Parasitology, and
Pathology. Animal Experimentation Protocols were reviewed and
approved by the Institutional Animal Care and Use Committees
(IACUC) of BIDMC. The approved protocol number is #139-
2009.
Mice
Eight to twelve week old male C57BL/6 wild type mice were
purchased from Taconic (MA).
General Reagents/Antibodies
LY294002, rapamycin and compound C were purchased from
EMD Corp Biosciences (Brookfield, WI); okadaic acid, carbenox-
olone, Z-VAD-fmk, necrostatin-1, BAPTA-AM and thapsigargin
were from Tocris Bioscience (Ellisville, MO); all other chemicals
were from Sigma-Aldrich (St. Louis, MO). Cell culture media were
purchased from ATCC and all other culture reagents from
Invitrogen (Carlsbad, CA). Lentiviral shRNA (Short hairpin RNA)
empty vector and constructs were purchased from the MISSION
H
RNAi library of Sigma-Aldrich and the viral power kit and
packaging cell line 293FT were obtained from Invitrogen.
Rabbit anti-P2X7 antibody (#APR-004) was obtained from
Alomone labs (Jerusalem, Israel); b-actin (AC-15, #ab6276) from
Abcam (Cambridge, MA); phospho-AKT (S473) (#9271), phos-
pho-PRAS40 (T246) (#2997), Phospho-AMPKa (T172) (#2535),
Phospho-AMPKb (S108) (#4181), phospho-ACC (S79) (#3661),
phospho-mTOR (S2481) (#2974), phospho-S6K (T389) (#9205),
phospho-S6 (S235/236) (#2211), phospho-4E-BP1 (T37/46)
(#2885), AKT (#9272), PRAS40 (#2691), AMPKa (# 2603),
AMPKb (#4150), ACC (#3676), mTOR (#2972), S6K (#9202),
S6 (#2317), 4E-BP1 (#9644), and LC3B (#2775) from Cell
Signaling Technology (Danvers, MA); HRP-conjugated goat anti-
mouse and donkey anti-rabbit IgG and the SuperSignal West
Femto Maximum Sensitivity Substrate reagents (#PI-34096) were
from Thermo Scientific (Rockford, IL).
Tumor Cell Lines
Syngeneic C57BL/6 murine MCA38 colon cancer cells (a gift of
Dr. Nicholas P. Restifo, National Cancer Institute) were provided
by Dr. Alan B. Frey at New York University School of Medicine
[26–28], and mouse melanoma cell line B16/F10 was from
American Type Culture Collection (ATCC, Manassas, VA). Cells
were also tested for Mycoplasma and other infections by mouse
IMPACT III PCR Profile via RADIL (Columbia, MO) and were
maintained, as previously described [15,20].
Assessment of Cell Viability and Proliferation
Cells (7.5610
3) were seeded into 96-well plates and cultured for
24 hr. Cells were then pulse-treated with ATP, BzATP, UTP, or
thapsigargin for different times, replaced with fresh culture media,
and grown for additional 16–24 hr. Cell viability was evaluated
using Cell Counting Kit-8 (CCK-8, Dojindo Molecular Tech. Inc.,
Rockville, MD) that measures the activity of cellular dehydroge-
nases (correlating with cell proliferation), as previously established
[20,29].
In Situ Cellular Analysis
Cells (7.5610
3) were seeded into Corning 3603 Black 96-well
plates and grown for 24 hr before exposed to ATP for a short
period of time. 16–24 hr later, cell growth was evaluated using the
Celigo Cytometer (Cyntellect, Inc., San Diego, CA). Brightfield
images of live cells were captured using the Celigo Cell Counting
application as described previously [20].
Real-time and Dynamic Monitoring of Cell Growth
(Proliferation and Viability)
These were performed using the xCELLigence RTCA MP
System (Roche Diagnostics, Indianapolis, IN) that non-invasively
quantifies adherent cell proliferation and viability using an
electronic readout called impedance (Cell Index) in real-time,
according to the manufacturer’s instructions. Cells (1.5610
4) were
seeded in 96X E-plates (#06472451001; Roche Diagnostics)
containing microelectronic sensor arrays and left in tissue culture
hood for 30 min at room temperature before inserting the plates
on the RTCA MP station in a humidified incubator under an
atmosphere of 5% CO2-95% air at 37uC. Cell growth were
immediately monitored up to 24 hr, at which point plates were
taken out and cells were treated with ATP. Cells were then
continuously monitored for additional 48 hr. Data were analyzed
with RTCA software. The Cell Index values (indicating adhesion,
Novel ATP-P2X7-mTOR Signaling Blocks Tumor Growth
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e60184spreading, proliferation and viability of the cells) were plotted
against growing times.
Clonogenic Assay
This was done as previously described with slight alterations
[30]. Briefly, MCA38 colon cancer cells (1610
6) were grown in 60-
mm culture dishes overnight to 60–70% confluency. Cells were
pulse treated with ATP, trypsinized and resuspended in culture
media. Then, 500 or 1000 cells were re-seeded into a 100-mm
culture dish and cultured for 12 days. Fresh media were replaced
every 3 days. On day 12, culture media were removed and
colonies were stained with 4 ml of Clonogenic Reagent (0.25%
1,9-dimethyl-methylene blue in 50% Ethanol) at room tempera-
ture for 45 min. Then Clonogenic Reagent was removed by
washing three times with PBS and blue colonies were counted and
photographed using a digital Nikon camera.
Antagonist-treatment Experiments
Cells were pre-incubated with antagonists compound C,
okadaic acid, LY294002, rapamycin, KN-62, suramin, carbenox-
olone, Z-VAD-fmk, necrostatin-1, or BAPTA-AM for 30 to
60 min before exposed to pulse treatment with ATP or control
vehicle DMSO. The final concentration of DMSO added to the
cells was ,0.1%. No effect of DMSO was observed.
Western Blotting
Cells (5610
5) were seeded into 6-well plates in culture media for
8 hr and then replaced with FBS-free starvation media. The next
day, cells were treated with freshly prepared compounds in
starvation media for various periods of time. Cells used for
examination of cellular autophagy were grown and treated in
regular culture media containing 10% FBS as serum-deprivation
induces autophagy. Treatments were stopped immediately by
washing the cells with ice-cold PBS three times. Cells were then
lysed in ice-cold modified-RIPA buffer (50 mM Tris-HCl, pH 7.4;
1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl) supple-
mented with Complete Proteinase Inhibitor Cocktails (Roche
Diagnostics) and Phosphatase Inhibitor Cocktails (Sigma-Aldrich).
The lysates were sonicated briefly on ice and centrifuged at
14,000 rpm for 10 minutes at 4uC. The measurement of protein
concentrations and detailed procedures of immunoblotting were
described previously [29,31].
Reverse Transcription-PCR (RT-PCR)
Total RNA were extracted and purified from cells using an
RNeasy kit (Qiagen, Germany). Reverse transcription was
conducted on 1 mg of total RNA using ABI Prism TaqMan
reverse transcription reagents (Cat#204054, Applied Biosystems,
Foster City, CA). The specificity of primers for murine P2
receptors and b-actin has been validated; sequences and PCR
conditions were used exactly as published previously [20,29,32].
Sequences of specific primer pairs for P2X7(a) and P2X7(k)
variants and PCR conditions were as previously described [33]. All
primers were obtained from Invitrogen.
Generation of P2X7 Deficient Cell Lines
MCA38 or B16/F10 cells were infected separately with an
empty shRNA vector control (pLKO.1-puro), or four different
mouse P2X7 shRNA (#1: NM-011027.1-105s1c1,
TRCN0000068572; #2: NM-011027.1-610s1c1,
TRCN0000068570; #3: NM-011027.1-876s1c1,
TRCN0000068568; and #4: NM-011027.1-1368s1c1,
TRCN0000068571) lentiviral transduction particles (Invitrogen),
according to the manufacturer’s instructions. Recombinant
lentiviral particles were produced by transient transfection of
293FT cells according to standard protocol (Invitrogen). Briefly,
6610
6 of 293FT cells were seeded in a 100-mm culture dish in
DMEM without antibiotics. The next day, cells reaching 90–95%
confluence were cotransfected with 3 mg of shRNA plasmids and
9 mg of ViraPower
TM Packaging Mix (an optimized proprietary
mix of three plasmids, pLP1, pLP2, and pLP/VSVG from
Invitrogen) using lipofectamine 2000 (Invitrogen). After 16 hr
culture medium was switched to regular growth medium and cells
were incubated for additional 48 hr. Conditioned cell culture
media containing recombinant lentiviral particles were harvested,
filtered through a 0.45 mm syringe filter, aliquoted, and used
immediately or stored at -80uC. MCA38 or B16/F10 cells were
infected with above cell culture supernatant containing lentiviral
particles in the presence of polybrene (8 mg/ml) for 24 hr. These
cells were replaced with regular growth media and cultured for
additional 48 hr to allow the expression of selection marker, and
then selected with puromycin (3 mg/ml for MCA38 cells and
1.5 mg/ml for B16/F10 cells) to generate stable cell lines encoding
empty vector shRNA and P2X7 shRNA, for at least 10 days. The
selected cell lines were tested to confirm diminished P2X7
expression, by Western blot analysis.
Ethidium Bromide Uptake Assay
This assay was performed as previously published [34] with
slight modifications. Briefly, cells (1.5610
4) were seeded into 96-
well plates. 24 hr later, cells were washed once with HBSS
containing Ca
2+/Mg
2+ and then incubated with 1.27 mM ethidium
bromide (a cell impermeable organic dye) in the absence or
presence of ATP (2.5 mM for MCA38 and 5 mM for B16/F10)
for different times, followed by whole cell fluorescence measure-
ment (in arbitrary units of fluorescence, AUF) at 544/610 nM
excitation/emission using the SoftMax Pro software on a
SpectraMax M5 Microplate Reader (Molecular Devices, Sunny-
vale, CA). Background fluorescence was subtracted to obtain the
ATP-elicited fluorescence.
Intracellular Nucleotide Measurements
Intracellular ATP, ADP, and AMP were determined by high-
performance liquid chromatography (HPLC) analysis as described
[35–37] with modifications. 2.5610
5 cells were seeded into 12-well
plates in culture media for 8 hr and then replaced with FBS-free
starvation media. 24 hr later, cells were treated with ATP in
starvation media for various times, followed by washing with ice-
cold HBSS five times to remove excess extracellular ATP. Some
wells were lysed with 200 ml of protein lysis buffer for protein
concentration measurement; and some wells were harvested with
600 ml of HBSS containing 5% 8 M perchloric acid and then
subjected to three frozen-thaw cycles. Lysates were scraped,
transferred to a 1.5 ml Eppendorf tube, pulse sonicated on ice, and
then stored at 280uC for subsequent HPLC analysis using a
Waters 484 system (Waters Corporation, Milford, MA) as
previously described [35–37].
Tumor Inoculations
This was preformed as previously described with slight
modifications [15,38]. Briefly, cells (2610
6) were seeded into
100-mm dishes. The next day, immediately after ATP treatment
(2.5 mM for 30 min), cells were washed with PBS, trypsinized, and
resuspended in culture media. 2610
5 of tumor cells were injected
s.c. into each flank of syngeneic 8–12 weeks old male C57BL/6
wild type mice. On day 14, the mice were euthanized and
examined for tumor growth.
Novel ATP-P2X7-mTOR Signaling Blocks Tumor Growth
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All data are represented as means 6 SEM of values (obtained
from three to six independent experiments in triplicates or
quadruplicates). All statistical analyses were performed using the
two-tailed Student’s t-test or the one-way analysis of variance
(ANOVA) followed by the LSD (least significant difference) test
when F was significant using SPSS 17 for Windows software.
Significance was defined as P,0.05.
Results
Antitumor Actions of ATP: in vitro and in vivo Studies
In this study, we first sought to shorten ATP treatment time
while still achieve efficient tumor-killing activity using two types of
tumor cells: MCA38 colon cancer cells and B16/F10 melanoma
cells, as in prior studies [20].
As shown in Fig. 1A–E (MCA38 cells) and in Fig. S1A–C (B16/
F10 cells), brief exposure of ATP (as short as 15 min) was able to
effectively kill both types of tumor cells (albeit with differential
potency), in a time- and dose-dependent manner. These findings
are in accord with our prior findings using repeated and/or
protracted exposure to ATP [20]. Cytotoxic ATP impacts many
aspects of tumor cell growth/survival: viability and proliferation
(Fig. 1A–C; Fig. S1A–C) as well as clonogenicity (Fig. 1D) in vitro;
and in vivo tumor growth in C57BL/6 wild type mice (Fig. 1E).
Strikingly, tumor cells responded to ATP cytotoxicity immediately,
as evaluated by real-time measurement of tumor cell growth (Fig.
S1B). Noteworthily, tumor cell death observed here was exclu-
sively attributed to the action of ATP as ADP or adenosine showed
no effects on tumor growth even at very high concentrations (up to
10 mM) for 1 hour (data not shown).
Moreover, tumor cell growth is tightly controlled by autophagy,
which is a fundamental process to maintain cellular homeostasis
and bioenergetics [39]. Induction of autophagy by manipulations
of autophagic pathways has been shown to have broad antitumor
potential (e.g. inhibiting xenograft tumor growth, reducing cancer
metastases, and inducing regression of existing cancers) [40,41]. As
such, we next examined the effects of eATP on tumor cell
autophagy. Light chain 3-II (LC3-II), a sensitive marker for
autophagy, was used here. Autophagy is generally suppressed in
the presence of serum. Herein, we observed that ATP markedly
enhanced LC3-II levels in tumor cells growing in complete growth
medium containing 10% serum, also in a time- and dose-
dependent fashion (Fig. 1F; Fig. S1D).
These results are suggestive of links between tumor cell growth
and autophagy that are co-responsive to cytotoxic ATP.
Signaling Regulatory Networks of PI3K/AKT, AMPK and
mTOR Impacted by ATP
ATP has been shown to activate mTOR signaling with co-
occurring elevation of LC3-II levels in microglial cells [42].
mTOR is a well-known key player in many critical cellular
processes such as proliferation, survival, autophagy, and metab-
olism [22,43]. Moreover, PI3K/AKT and AMPK pathways are
the two well-established positive and negative upstream arms of
mTOR, respectively [44,45]. It has been demonstrated that ATP
induces depletion of nuclear phosphorylated AKT [25].
Hence, we first examined the phosphorylation of pathway
components of mTOR (inclusive of mTOR, p70 S6 kinase (S6K),
S6 ribosomal protein, and translation repressor protein 4E-BP1),
PI3K/AKT (AKT and PRAS40), and AMPK (AMPKa, AMPKb
and acetyl-CoA carboxylase (ACC)) in response to eATP. Time-
and dose-dependent decreases in phosphorylated levels of mTOR
and PI3K/AKT signaling molecules concomitant with increases in
AMPK cascade were noted (Fig. 2A and B; Fig. S2A). These
effects occurred regardless of the cell growing conditions (serum-
starvation medium or complete growth medium) (data not shown).
To further delineate regulatory networks for ATP-induced
alterations in mTOR, PI3K/Akt and AMPK signaling, we
performed the following experiments using pharmacologic inhib-
itors to these pathways. Phosphorylation of S6K, a sensitive and
immediate downstream target of mTOR, was used to indicate
changes in activation status of mTOR. First, as noted in Fig. 2C,
okadaic acid (OA), a potent inhibitor of protein phosphatase 1
(PP1) and protein phosphatase 2A (PP2A) preventing p-Akt
depletion, fully abolished ATP-mediated depletion of p-AKT
whereas with no effects on depletion of its conventional target p-
PRAS40 (Thr246). However, okadaic acid failed to reverse ATP-
induced inhibition on mTOR and cell growth by (Fig. 2C). In
parallel, inhibitor to PI3K (LY294002) could almost completely
block basal phosphorylation of AKT-PRAS40-S6K (Fig. 2C). As
expected, rapamycin (inhibitor of mTOR) suppressed S6K
phosphorylation, to a similar extent as ATP (Fig. 2C). These data
suggest that PI3K/AKT-PRAS40 is an upstream of mTOR in
tumor cells under physiological conditions but not involved in
ATP-induced mTOR inactivation.
Second, blockade of AMPK activation by compound C (CC)
completely rescued ATP-elicited de-phosphorylation of S6K
(Fig. 2D; Fig. S2B). Intriguingly, ATP-mediated depletion of p-
PRAS40, (as suggested by its name proline-rich AKT substrate of
40 KDa) a well-recognized classical downstream target of AKT,
was near wholly abolished by compound C, as similar to that of p-
S6K (Fig. 2D; Fig. S2B). These data are implicative of a novel
AMPK-PRAS40-mTOR axis responding to tumoricidal ATP.
Finally, we explored the links between mTOR signaling and
tumor cell autophagy that are altered by eATP. Indeed, mTOR is
thought to suppress autophagy [46]. We observed that rapamycin
dramatically enhanced LC3-II levels in tumor cells, similar to ATP
(Fig. 2E, top). Furthermore, okadaic acid or compound C could
substantively abrogate LC3-II at basal levels or induced by ATP
(Fig. 2E, bottom). However, okadaic acid or compound C alone
failed to rescue ATP-elicited tumor cell death (Fig. S2C). Indeed,
compound C treatment alone slightly but significantly reduced cell
growth (P=0.002; Fig. S2C). Moreover, blockade of either PI3K/
AKT (by LY294002) or mTOR (by rapamycin), or both, was able
to induce cell death but with much less potency when compared to
ATP (Fig. S2C).
Taken together, these data indicate that cytotoxicity of ATP is
mediated by two independent signaling pathways, namely AMPK-
PRAS40-mTOR and PI3K/AKT, that synergistically perturb
(otherwise tightly controlled) balance between growth and
autophagy in tumor cells whereby eventually causing cell death.
The inability to rescue ATP-evoked tumor cell death by blocking
either pathway inhibition induced by ATP imply that upstream
molecule(s) must exist for these two ATP-initiated signaling
cascades that are urgently needed to be identified for targeted
cancer therapy.
P2X7 Receptor is the Control Nexus of ATP-elicited
Tumor Cell Death
Therefore, we next focused on searching for the purinergic
receptor(s) transmitting extracellular cytostatic ATP-mediated
signals to these intracellular regulatory networks as alluded above.
We first analyzed mRNA expression of P2 receptor panels in
MCA38 cells using RT-PCR (data with B16/F10 cells have been
published previously (ref)). MCA38 cells expressed mRNA
transcripts for P2X3 (minimal), P2X4, P2X5, P2X6 (weaker),
P2X7, P2Y1, and P2Y12–14 (Fig. 3A).
Novel ATP-P2X7-mTOR Signaling Blocks Tumor Growth
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e60184Figure 1. Antitumor effects of ATP on MCA38 colon cancer cells: in vitro and in vivo studies. A–C) Dose- and time-dependent responses
of MCA38 cells to ATP cytotoxicity at 24 hr after treatment: cell viability/proliferation by Cell Counting Kit-8 (CCK-8) (A); real-time and dynamic
monitoring of cell growth by xCELLigence instrument (B); and representative bright field images of live cells by Celligo Cell Counting application (C).
D) Top, colony numbers of MCA38 cells on day 12 post ATP treatment. Bottom, representative images of clonogenic assay dishes. E) Top, tumor
weight of C57BL/6 mice implanted with untreated (Ctrl) or ATP-treated MCA38 cancer cells on day 14 (n=12 per group). Bottom, representative
tumors on day 14. Scale bar, 0.5 cm. F) Western blots of LC3-II, a sensitive indicator for autophagy, using MCA38 cells treated with ATP at various
doses and times as indicated. b-actin serves as a loading control. Error bars, mean 6 SEM. Data represent three to six experiments.
doi:10.1371/journal.pone.0060184.g001
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at least partially, mediated via P2X7. We then treated tumor cells
with BzATP, a more potent prototypic P2X7 receptor agonist. As
presented in Fig. 3, BzATP-triggered growth inhibition (Fig. 3B;
Fig. S3A) and signaling alterations (Fig. 3D) of tumor cells near
exactly recapitulates the same pattern observed with ATP. In
contrast, UTP, an agonist of P2X5, P2Y2, P2Y4, and P2Y6,
exhibited no effects on tumor cell growth (Fig. 3C). Moreover, the
global P2 receptor antagonist suramin (inhibiting P2X1–3, P2X5,
P2Y1–2, P2Y6, and P2Y11–13) was unable to relieve the suppressive
actions of ATP on phosphorylation of AKT, PRAS40 and S6K
(Fig. S3B) as well as tumor cell growth (data not shown), although
Figure 2. Intracellular mTOR, AKT, and AMPK signaling and induction of autophagy are impacted by cytotoxic ATP. A–B) Western
blot analysis of signaling components of mTOR (A), AKT and AMPK (B), in MCA38 cells after ATP treatment at different times as indicated. Inhibition of
mTOR and AKT with concurrent stimulation of AMPK signaling was noted. C–D) Delineation of ATP-elicited intracellular signaling cascades by
blockade of certain component using specific inhibitors, determined by Western blotting. OA (okadaic acid): 100 nM; LY294 (LY294002): 50 mM; RAPA
(rapamycin): 100 nM; CC (compound C): 20 mM. E) Impacts of pathway inhibitors on autophagy in MCA38 cells, as examined by Western blots of LC3-
II. b-actin is the loading control. Data represent three to six experiments.
doi:10.1371/journal.pone.0060184.g002
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S3B). In parallel, selective P2X7 receptor antagonist KN62
virtually counteracted ATP-mediated signaling alterations, in a
time- and dose-dependent manner (Fig. 3E; Fig. S3C and D).
These findings are evident of P2X7 receptor as the upstream
control node of ATP-initiated signaling regulatory networks.
Knockdown of P2X7 Protects Tumor Cells from
Antitumor Function of ATP
However, KN62 is also a selective inhibitor of Ca
2+/calmod-
ulin-dependent protein kinases II (CaM kinases II), though
exerting more potent inhibition on P2X7 receptor. CaM kinases
II has been shown to involve in pathophysiological signaling to
thereby modulate many fundamental cellular processes e.g.
proliferation and apoptosis, and has been linked to ATP-provoked
purinergic signaling in endothelial cells [47]. As such, we
generated stable P2X7 deficient tumor cells using lentiviral
shRNA method as detailed in Materials and Methods. Out of
four P2X7 shRNAs, one effectively blocked P2X7 protein
expression in both tumor cell lines (Fig. 4A; Fig. S4A). These
are defined as P2X7 KD and used for all subsequent analyses.
Strikingly, P2X7 deficiency near fully deviated all cytostatic
ATP-mediated effects on tumor cells: signaling regulatory
Figure 3. ATP-induced tumor cell death is modulated via P2X7-mTOR axis. A) Reverse transcription-PCR (RT-PCR) analysis of mRNA
expression of P2 receptors in MCA38 cells. Size standards (Std) are shown in the left lane. B–C) Cell viability of MCA38 cells at 24 hr post treatment
with BzATP (B) or UTP (C), as determined by CCK-8. Data are expressed as a percentage of untreated controls. D) Impacts of BzATP on AKT, AMPK, and
mTOR signaling, as analyzed by Western blot. E) Blockade of P2X7 by antagonist KN62 abrogated ATP-induced inhibition on mTOR signaling in
MCA38 cells, as evaluated by Western blotting. b-actin is shown as a loading control. Error bars, mean 6 SEM. Data represent three to four
experiments.
doi:10.1371/journal.pone.0060184.g003
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PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e60184Figure 4. Knockdown of P2X7 decreases antitumor activity of ATP. A) Western blots for P2X7 using lysates from MCA38 cells after knocking
down P2X7 using lentiviral shRNAs. B–G) Differential effects of ATP on control knockdown (KD Ctrl) and P2X7 deficient (P2X7 KD) MCA38 cells: AKT-
and AMPK-mTOR signaling by Western blotting (B); cell viability by CCK-8 (C); representative live cell images by Celligo (D); real-time measurement of
cell growth by xCELLigence (E); clonogenicity by colony formation assay (F); and autophagy by Western blotting (G). b-actin is a loading control. Error
bars, mean 6 SEM. Data represent three experiments.
doi:10.1371/journal.pone.0060184.g004
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colony-forming capacity (Fig. 4F), and autophagy (Fig. 4G; Fig.
S4F). Further, knockdown of P2X7 conferred tumor cells with
higher growth and clonogenic potential, as compared to control
knockdown (Ctrl KD) cells (Fig. 4E and F; data not shown).
Characterization of Extracellular ATP-elicited P2X7
Receptor Channel Functions
Next, we sought to assess the impact of tumoricidal concentra-
tions of extracellular ATP on P2X7 receptor channel functionality.
First, we examined the expression of P2X7 splice variants
P2X7(a) and P2X7(k) in tumor cells, as it has been recently
reported that the P2X7(k) variant exhibits a much higher ligand
sensitivity and transduces signals more efficiently than the P2X7(a)
variant [33]. As shown in Fig. 5A, both MCA38 and B16/F10
cells only express the P2X7(a) variant at the mRNA level.
Second, P2X7 channel function, specifically non-selective pore
activity, was evaluated using ethidium bromide uptake assays. We
noted that ATP markedly stimulates ethidium bromide uptake in
both cell lines (Fig. 5B and C).
Third, these demonstrated ‘‘porin’’ channels could facilitate
efflux of intracellular adenine nucleotides thereby perturbing
intracellular nucleotide levels. It is known that an increase in the
AMP/ATP ratio is linked to the mechanism of AMPK activation.
Therefore, we then measured levels of intracellular ATP, ADP and
AMP by HPLC in tumor cells pulsed treated with ATP for 15 and
30 min. Substantial decreases in intracellular ATP levels were
observed (Fig. 5D and E), concurrent with significant increases in
intracellular ADP and AMP levels as well as AMP/ATP ratios
(Fig. 5D and E). These observations are compatible with ATP-
P2X7 triggered AMPK activation, as also noted above (Fig.2; Fig.
S2).
Fourth, by performing antagonist studies, we then confirmed
that PI3K/AKT and AMPK/mTOR signaling altered by P2X7
activation are not linked to other native pore-forming transporters
(inclusive of pannexin- or connexin-type channels) nor reactive
oxygen species (ROS), as previously reported [19,48]. Neither
carbenoxolone (a pharmacological inhibitor of pannexin- or
connexin-type channels) nor N-acetyl-cysteine (a broad anti-
oxidant) could substantively impact ATP-induced P2X7 signaling
cascades (Fig. S5A).
We have previously demonstrated that ATP-P2X7 elicited
tumor cell death is mediated via both apoptosis and necrosis [20],
in keeping with fluxes in intracellular nucleotides, as also noted
above. We now show that P2X7 activation can also induce tumor
cell autophagy (Fig. 1F; Fig. 4G; Fig. S1D; Fig. S4F). Importantly,
none of the specific pharmacological inhibitors (e.g. Z-VAD-fmk, a
pan-caspase inhibitor or the necroptotic inhibitor necrostatin-1;
various doses of compounds ranging from 12.5 to 200 mM were
tested) when tested alone could counteract ATP-induced tumor
cell death (Fig. S5B; data not shown).
Calcium Signaling is not Involved in ATP-P2X7 Mediated
Tumor-killing Activity
Given that P2X7 is a prototypic ligand-gated ion channel, the
activation by high ATP levels often leads to a robust increase of
Ca
2+ influx into cells [42]. To determine whether the influx of
Ca
2+ is involved in ATP-evoked cellular effects, two experimental
approaches were employed using two chemical compounds that
differently alter cytosolic Ca
2+ levels: BAPTA-AM, a selective cell-
permeable calcium chelator to block intracellular Ca
2+ stores, and
thapsigargin (TG), a potent inhibitor of endoplasmic reticulum
Ca
2+-ATPase causing an immediate increase in cytoplasmic Ca
2+
levels.
First, we found that BAPTA-AM failed to relieve ATP-induced
mTOR inactivation and LC3-II increase (Fig. 6A and B; Fig.
S6A). Instead, BAPTA-AM completely abolished basal levels of
PI3K/AKT and mTOR signaling and LC3-II with no effects on
AMPK signaling (Fig. 6A and B; Fig. S6A), associated with
marked induction of cell death (Fig. S6B). This supports a role of
Ca
2+ in tumor cell growth under physiological conditions but not
in cellular responses to cytotoxic ATP.
In contrast, such Ca
2+-ATPase inhibitors as thapsigargin (TG),
a potent antitumor agent can be used to induce autophagy in
mammalian cells, were able to induce immediate cell death
(Fig. 6C; Fig. S6C) and activation of AMPK pathway (Fig. 6D;
Fig. S6D), but exerted no effects on PI3K/AKT and mTOR
signaling transduction nor on autophagy (Fig. 6B and D; Fig.
S6D). These data affirm that Ca
2+ influx is not involved in the
tumoricidal function of ATP having distinct molecular mechanism
from the antitumor action of thapsigargin.
In summary, we infer that high-levels of extracellular ATP act
on one novel P2X7-AMPK-PRAS40-mTOR axis and one
conventional P2X7-PI3K/AKT axis to induce autophagy and
inhibit growth that ultimately result in tumor cell death (as
illustrated in Fig. 7).
Discussion
We have previously reported that protracted exposure to ATP,
a putative danger signal enhances antitumor immunity, directly
inhibits tumor cell growth and induces cell death, at least in part
via activation of the purinergic receptor P2X7 [20]. In the present
study, we further show that acute and self limited treatment with
exogenous ATP is able to trigger a prompt cellular response that
effectively hinders tumor growth, both in vitro and in vivo. More
importantly, we provide a novel molecular mechanism that further
links extracellular ATP-P2X7 signals to the intracellular mTOR
pathway, one of the critical control nexuses of signaling
transduction networks and used as a cancer therapeutic target
[22,23].
mTOR is a well-known sensor for extracellular nutrients and
growth factors converging many crucial signals e.g. Ras/mitogen-
activated protein kinase (MAPK) and PI3K/AKT to control
tumor cell growth [43] and is known to regulate fundamental
cellular functions inclusive of proliferation/growth, survival,
migration, adhesion, autophagy, and metabolism [22]. The
regulation networks of mTOR are very complex.
It has recently been shown that PRAS40 is a raptor-interacting
protein inhibiting S6K1 phosphorylation and cell growth and
AKT-mediated phosphorylation of PRAS40 prevents its suppres-
sion on mTOR [44]. Activation of P2X7 by ATP has been shown
to cause a rapid depletion of nuclear phosphorylated AKT in non-
small cell lung cancer cells A549 [25]. In addition, AMPK, a key
player in maintaining energy homeostasis that is activated in
response to cellular stress, is a negative upstream regulator of
mTOR signaling [45]. Extracellular ATP could also activate
AMPK, albeit independent of P2X7 in endothelial cells [47].
Intriguingly, distinct from the conventional mTOR modulation
networks, we herein identify a novel AMPK-mTOR regulatory
axis by way of de-phosphorylating Thr246 of PRAS40, the
classical AKT substrate, in parallel with the previously-shown
PI3K/AKT pathway, in response to tumoricidal ATP-P2X7
signaling (as illustrated in Fig. 6). Instead, PRAS40 is not the
downstream component of ATP-P2X7-PI3K/AKT cascade.
Moreover, we further note that in tumor cells under physiological
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PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e60184Figure 5. Characterization of P2X7 receptor function activated by tumoricidal ATP. A) Examination of P2X7(a) or P2X7(k) variant
expression in MCA38 and B16/F10 cells by RT-PCR with specific primer pairs for P2X7(a) or P2X7(k). Size standards (Std) are shown in the left lane. B–
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PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e60184conditions, PI3K/AKT and AMPK converge on PRAS40 to
inversely modulate mTOR activation whereby tightly controlling
the balance of cell growth and autophagy to govern tumor cell
growth. This is the first article to report the de-phosphorylation of PRAS40
at Thr246 by AMPK, which is operational as an upstream suppressor of
mTOR.
Furthermore, we show that tumoricidal ATP concentrations
trigger non-selective pore-forming activity, characteristic of P2X7
activation. However, the noted ATP-P2X7-induced blockade of
mTOR and PI3K/AKT signaling associated with tumor cell
death is not regulated via pannexin- or connexin type channels nor
by varied levels of mitochondrial ROS production, as previously
reported in prior studies [19,48]. The observed process in our
studies also appears independent of the more well established
P2X7 activation-elicited influx of Ca
2+, such as seen in microglial
cells and macrophages [42]. These latter observations are in line
with prior studies showing that ATP triggered P2X7-mediated
human leukemia cell death is independent of increased Ca
2+ influx
[49]. However, basal levels of Ca
2+ stores do appear essential for
the maintenance of PI3K/AKT-PRAS40-mTOR activation and
tumor cell growth under normal growing conditions.
We further are able to link activation of AMPK, a well-known
classical energy sensor, with increases of intracellular AMP/ATP
ratios; both are altered by high extracellular ATP levels.
Additionally, mTOR has also been established as an intracellular
ATP/energy sensor [50]. Interestingly, our observations of time-
and dose-dependent alterations of mTOR signaling by extracel-
lular ATP suggest the possibility that mTOR also might function
as a sensor for extracellular ATP levels in the tumor microenvi-
ronment.
Moreover, experiments with both temporary blockade of P2X7
by non-competitive antagonists e.g. KN62 and stable knockdown
by lentiviral P2X7 shRNA imply that tumoricidal activity of ATP
is, to a very great extent, mediated through P2X7 receptor
signaling. Importantly, P2X7-deficient tumor cells exhibit greater
potential of growth and clonogenicity. This observation is in
keeping with a previous article reporting anthracycline treated
breast cancer patients with loss of function allelic mutations of
P2X7 develop metastatic disease more rapidly [9]. Collectively,
C) ATP-stimulated ethidium bromide uptake in MCA38 (B) and B16/F10 cells (C). D–E) Effects of extracellular ATP on intracellular levels of ATP, ADP
and AMP in MCA38 (D) and B16/F10 cells (E) were measured by HPLC. Values of MCA38 AMP concentrations are multiplied five fold for the sole
convenience of plotting on the same axes. Error bars, mean 6 SEM. Data represent three experiments.
doi:10.1371/journal.pone.0060184.g005
Figure 6. ATP-P2X7-mTOR elicited tumor cell death does not involve calcium signaling. A) Effects of BAPTA-AM on ATP/P2X7-initiated
AKT, AMPK and mTOR signaling in MCA38 cells, as examined by Western blotting. B) Effects of BAPTA-AM and thapsigargin (TG) on autophagy as
determined by Western blots of LC3-II. C–D) Impacts of thapsigargin (TG) on MCA38 cell growth by CCK-8 (C); and Akt, AMPK and mTOR signaling by
Western blot analysis (D). b-actin is the loading control. Error bars, mean 6 SEM. Data represent three experiments.
doi:10.1371/journal.pone.0060184.g006
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also link high levels of extracellular ATP to intracellular signaling
transduction networks thereby promoting tumor cell death.
It has been demonstrated that any P2X7 knockdown results in a
compensatory increase in expression of P2X4, another purinergic
receptor with similar function to P2X7 yet less investigated/
understood [51]. We also observed an increased P2X4 expression
in both types of P2X7 deficient tumor cells (data not shown) that
might be responsive to cytotoxic ATP. We have excluded the
possibility of involvement of other type 2 purinergic receptors viz.
P2X1–3, P2X5, P2Y1–2, P2Y4, P2Y6, and P2Y11–13, in ATP-elicited
tumor cell death noted here by performing studies using P2
receptor agonist/antagonist panels (Fig. 3; Fig. S3).
We have recently defined that both apoptosis and necrosis are
linked to ATP-P2X7 promoted tumor cell death [20]. However,
suppression of either apoptosis or necroptosis alone fails to
attenuate ATP-elicited tumor cell death here. Indeed, we can
further link P2X7 activation to induction of tumor autophagy.
These data suggest that ATP-induced tumor cell death involves
combinational and concurrent cellular events including opening of
porin channel, efflux of cytosolic adenine nucleotides, transduction
of signaling cascades, induction of apoptosis/necrosis/autophagy,
as well as inhibition of proliferation/survival. Hence, blockade of
any single process alone is unable to counteract tumor-killing
function of ATP.
This supposition could be supported by the experimental
observations that only blockade of P2X7 (by pharmacologic
inhibition or genetic knockdown) can substantively attenuate
tumoricidal activity of ATP. In contrast, none of the down stream
pathway inhibitors have comparable activities, despite near full
abrogation of the respective signaling cascade (such as compound
C, okadaic acid).
Ideally, to achieve maximal efficacy of cancer therapy,
integration of all potential antitumor actions would be required.
Implicated mechanisms (as for purinergic mediators) include ATP-
mediated antitumor immune responses, direct induction of tumor
cell death, and blockade of tumor angiogenesis. A good proof-of-
concept example is the recent study conducted by Wang et al.
demonstrating that co-targeting of tumor cells and elicitation of
antitumor immune responses dramatically inhibited trastuzumab-
resistant breast cancers [52].
The observed variable impacts of P2X7 activation on cell
viability and growth remain controversial. Such divergent effects
appear to be impacted by kinetics and levels of extracellular ATP
fluxes as well as being highly cell-type dependent. Based on
published literature, it seems that P2X7 activation at low level
facilitates growth/survival of certain types of tumor cells [53]
whereas the extracellular nucleotide at high level promotes cell
death [1]. In this study, we focused on the molecular mechanism(s)
underpinning the direct cytotoxic effects of high levels of ATP on
tumor cells. Our data are also in agreement with the recent
findings showing that extracellular ATP causes human colon
cancer cell death [19].
One of the major issues in cancer therapy is that disruption of
one signaling component often induces compensatory pathways
because of negative feedback regulations (e.g. rapalogs [23,24]) or
loss of suppressors (e.g. PTEN [54]). These issues will ultimately
lead to acquired resistance. Thus, combined targeting of multiple
pathways, especially the upstream components, has been actively
pursued and proven to be a better approach [55]. Hence, we
suggest a more promising cancer target, P2X7, as the upstream
component of a tumoricidal ATP signal transduction network in
that activation of it leads to concurrent and efficacious blockade of
both PI3K/AKT and mTOR pathways, without affecting escape
mechanisms as those often seen with rapalogs nor PTEN
expression (data not shown).
High levels of pericellular ATP have been observed in tumor
tissues of tumor-bearing mice after radiation and chemotherapy
[10,56]. First, ATP released by such dying tumor cells, has been
recently identified as a novel danger signal to enhance dendritic
cell-primed tumor specific CD8 T cell cytotoxicity via activation of
P2X7-NLRP3 inflammasome [9,10]. Thus, ATP augments
antitumor immune responses. Secondly, high levels of ATP
efficiently kill tumor cells [20] that are further affirmed herein.
Third, ATP also exerts direct cytotoxicity on vascular endothelial
cells such as liver sinusoidal endothelial cells that could limit tumor
angiogenesis, also in a dose- and time-dependent fashion [20].
Therefore, it is feasible to propose that ATP release from dying
tumor cells evoked by immuno/chemo/radiotherapy could
augment antitumor activity via a positive feedback reaction, and
that co-altering the tumor microenvironment in such a fashion
that would keep ATP levels high for a short period (15 to 60
minutes) would augment the efficacy of anti-cancer therapy.
CD39/ENTPD1, the dominant ectonucleotidase expressed by
the vasculature and immune cells (including leukocytes, mono-
cytes/macrophages, dendritic cells, B cells, Treg, natural killer
(NK)/T, and type 17 effector T (Th17) cells), tightly controls
extracellular ATP levels by hydrolyzing ATP to ADP and then
AMP [2,16,21]. We have shown that vascular CD39 promotes
tumor growth by scavenging extracellular ATP [20]. In addition,
many types of tumor cells intrinsically express CD39 and ecto-59-
nucleotidase (or CD73; degrading AMP to adenosine) being able
to generate the immunosuppressant adenosine per se, and thereby
dampen effector cell function [2,57]. The tumor cells used in this
Figure 7. Schematic illustration of how PI3K/AKT, AMPK and
mTOR regulatory networks distinctly control tumor cell growth
in response to high levels of ATP. A) In the presence or absence of
serum, tumor cell growth is dictated by cellular autophagy and growth/
survival signals that are tightly controlled by PI3K/AKT and AMPK
pathways convergent on mTOR by way of PRAS40. Physiological Ca
2+
stores are absolutely required to maintain basal activation of the PI3K/
AKT-PRAS40-mTOR signaling and cell growth. B) In a tumor microen-
vironment with pericellular ATP likely to be at high levels, activation of
P2X7 on tumor cells leads to concurrent blockade of the mTOR
signaling by way of AMPK-PRAS40 axis and the PI3K/AKT pathway.
These are the two critical control nexuses for autophagy induction and
growth inhibition that ultimately lead to tumor cell death. Ectonucleo-
tidase CD39 protects tumor cells from antitumor activity of high levels
of extracellular ATP [15,20]. Pathway key: R: Stimulation; –ı: Inhibition.
doi:10.1371/journal.pone.0060184.g007
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not express CD39/CD73 [15,20]. Moreover, our accumulating
data also show that CD39 expression by vascular cells per se is an
absolute requisite for tumor angiogenesis [15,38,58], and that
Treg-associated CD39 and CD73 produces adenosine to impede
antitumor immune responses [15,59].
Recently, we have further demonstrated that blockade of CD39
enzymatic activity using a specific pharmacological inhibitor,
POM-1 (Polyoxometalate-1), greatly abrogates tumor growth in
transplanted tumor models [15]. This has been attributed, by us,
to be mediated via: defective tumor angiogenesis, augmented
antitumor function of NK cells, as well as enhanced tumor-killing
activity of high levels of ATP [15,20]. In parallel, modifications of
purinergic signaling/CD39 as a promising target in cancer therapy
have also been endorsed independently by other laboratories and
discussed in detail in two recent articles [60,61].
In summary, we describe novel purinergic suppression mech-
anisms involving AMPK-PRAS40 novel elements of the mTOR
signaling network, which are operational with PI3K/AKT
established pathways. Our studies affirm the therapeutic potential
of purine-related drugs, which might be used to simultaneously
target tumor cells and the host immune system, as well as tumor
angiogenesis.
Supporting Information
Figure S1 Extracellular ATP is cytotoxic for B16/F10
melanoma cells. A–C) Dose- and time-dependent responses of
B16/F10 cells to ATP killing: cell viability/proliferation CCK-8
(A); real-time cell growth by xCELLigence (B); and representative
live cell images by Celligo (C). D) Dose-dependent induction of
autophagy by ATP in B16/F10 cells, as determined by Western
blots of autophagy marker LC3-II. b-actin serves as a loading
control. Error bars, mean 6 SEM. Data represent three
experiments.
(TIF)
Figure S2 Time- and dose-dependent responses of AKT,
AMPK and mTOR to ATP-mediated signaling responses
in tumor cells. A) Western blots for AKT, AMPK and mTOR
pathway components post ATP treatment at various times and
doses in B16/F10 cells (A). B) AMPK inhibitor compound C (CC)
fully rescued ATP-induced mTOR inhibition in MCA38 cells in a
dose-dependent manner, as examined by Western blotting. C)
Effects of pathways inhibitors on MCA38 cell growth, as examined
by CCK-8 and expressed as percentage of untreated controls.
Data represent three to four experiments.
(TIF)
Figure S3 P2 receptor agonist and antagonist studies. A)
B16/F10 cell viability at 24 hr post BzATP treatment, as
determined by CCK-8. Data are normalized to untreated controls.
B) Effects of suramin (100 mM,) on AKT, AMPK and mTOR
pathways in MCA38 cells, as examined by Western blot analysis.
C–D) P2X7 antagonist KN62 counteracted ATP-evoked signaling
transduction of AKT, AMPK, and mTOR in MCA38 cells (C)
and B16/F10 cells (D), in a dose-dependent manner, as evaluated
by Western blotting. b-actin is the loading control. Error bars,
mean 6 SEM. Data represent three to four experiments.
(TIF)
Figure S4 P2X7 deficient B16/F10 cells. A) Knockdown of
P2X7 in B16/F10 cells was validated by Western blotting. B–F)
Differential effects of ATP on control and P2X7 KD B16/F10
cells: AKT- and AMPK-mTOR signaling by Western blotting (B);
cell viability by CCK-8 (C); representative live cell images by
Celligo (D); and real-time monitoring of cell growth by
xCELLigence (E); and autophagy by Western blots of LC3-II
(F). b-actin is used as the loading control. Error bars, mean 6
SEM. Data represent three experiments.
(TIF)
Figure S5 Assessment of carbenoxolone, N-acetyl-cys-
teine, Z-VAD-fmk, and necrostatin-1 on ATP-P2X7
induced signaling or tumor cell death. A) Effects of
carbenoxolone (CBX) and N-acetyl-cysteine (NAC) on ATP-
initiated AKT, AMPK and mTOR signaling in MCA38 and B16/
F10 cells, as examined by Western blot analysis. B) Effects of Z-
VAD-fmk and necrostatin-1 on ATP-induced MCA38 cell death,
as examined by CCK-8 and expressed as percentage of untreated
controls. b-actin served as a loading control. Error bars, mean 6
SEM. Data represent three experiments.
(TIF)
Figure S6 Impact of calcium signaling on AKT, AMPK
and mTOR signaling transduction and tumor cell
growth. A) Effects of BAPTA-AM on AKT, AMPK and mTOR
signaling in B16/F10 cells, as analyzed by Western blotting. B)
Effects of BAPTA-AM on MCA38 cell growth, as examined by
CCK-8 and expressed as percentage of untreated controls. C–D)
Impacts of thapsigargin (TG) on B16/F10 cell viability by CCK-8
(C); and AKT, AMPK and mTOR signaling by Western blot
analysis (D). b-actin is shown as a loading control. Error bars,
mean 6 SEM. Data represent three experiments.
(TIF)
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